window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : December 6, 2025

  • News
  • About Us
Contact Us

Metabolism

  • Clinical Trials

    Orforglipron: Lilly’s first oral GLP 1 pill cuts A1C by up to 1.6% and trims 16 lbs in Phase 3 trial

    April 22, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2025 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • CNS Pharmaceuticals announces primary analysis of Berubicin in second line treatment of glioblastoma multiforme
    Categories: Central Nervous System, Clinical Trials, Pharmaceuticals and therapeutics, Research & Development
  • Horiba UK launches philanthropic foundation to advance scientific research and broaden STEM participation
    Categories: Facilities and infrastructure, Healthcare leadership, Research & Development
  • Net-zero in action: ABB powers GSK’s sustainability leap in Singapore
    Categories: CDMOs & Manufacturing, Market Access & Commercialization, Sustainability
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top